PT - JOURNAL ARTICLE AU - Li, Deming AU - Butala, Ankur A. AU - Moro-Velazquez, Laureano AU - Meyer, Trevor AU - Oh, Esther S. AU - Motley, Chelsey AU - Villalba, Jesús AU - Dehak, Najim TI - Automating the analysis of eye movement for different neurodegenerative disorders AID - 10.1101/2023.05.30.23290745 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.30.23290745 4099 - http://medrxiv.org/content/early/2023/08/07/2023.05.30.23290745.short 4100 - http://medrxiv.org/content/early/2023/08/07/2023.05.30.23290745.full AB - The clinical observation and assessment of extra-ocular movements is common practice in assessing neurological disorders but remains observer-dependent and subjective. In the present study, we propose an algorithm that can automatically identify saccades, fixation, smooth pursuit, and blinks using a non-invasive eye-tracker and, subsequently, elicit response-to-stimuli-derived interpretable features that objectively and quantitatively assess patient behaviors. The cohort analysis encompasses persons with mild cognitive impairment (MCI) and Alzheimer’s disease (AD), Parkinson’s disease (PD), Parkinson’s disease mimics (PDM), and controls (CTRL). Overall, results suggested that the AD/MCI and PD groups exhibited significantly different saccade and pursuit characteristics compared to CTRL when the target moved faster or covered a larger visual angle during smooth pursuit. When reading a text passage silently, more fixations were an AD/MCI-specific feature. During visual exploration, people with PD demonstrated a more variable saccade duration than other groups. In the prosaccade task, the PD group showed a significantly smaller average hypometria gain and accuracy, with the most statistical significance and highest AUROC scores of features studied. The minimum saccade gain was a PD-specific feature distinguishing PD from CTRL and PDM. Furthermore, the PD and AD/MCI groups displayed more omitted antisaccades and longer average antisaccade latency than CTRL. These features, as oculographic biomarkers, can be potentially leveraged in distinguishing different types of NDs in their early stages, yielding more objective and precise protocols to monitor disease progression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Richman Family PMCoE-AD Venture Discovery Fund and Consolidated Anti-Aging Foundation Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants underwent informed consent. The IRB of Johns Hopkins Medicine gave ethical approval for the data collection and this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors plan to share all data produced in the present study in the future.